Contact

All Stories

  1. Dose-Dependent Efficacy of a Riboflavin and Ultraviolet Light-Inactivated Whole-Virion SARS-CoV-2 Vaccine in a Hamster Infection Challenge Model

    Article • Vaccines, January 2026, MDPI AG

    Professor Raymond Goodrich

  2. In memoriam: Dr. Dirk de Korte

    Article • Transfusion, May 2024, Wiley

    Professor Raymond Goodrich

  3. Emerging Pathogen Threats in Transfusion Medicine: Improving Safety and Confidence with Pathogen Reduction Technologies

    Article • Pathogens, July 2023, MDPI AG

    Professor Raymond Goodrich

  4. Emerging Pathogen Threats in Transfusion Medicine and the Role of Pathogen Reduction Technologies

    Article • May 2023, MDPI AG

    Professor Raymond Goodrich

  5. Killing Monkeypox Virus in Blood Products

    Article • PLOS One, January 2023, PLOS

    Professor Raymond Goodrich

  6. Preservation of neutralizing antibody function in COVID‐19 convalescent plasma treated using a riboflavin and ultraviolet light‐based pathogen reduction technology

    Article • Vox Sanguinis, April 2021, Wiley

    Professor Raymond Goodrich

  7. A Whole Virion Vaccine for COVID-19 Produced via a Novel Inactivation Method and Preliminary Demonstration of Efficacy in an Animal Challenge Model

    Article • Vaccines, April 2021, MDPI AG

    Professor Raymond Goodrich

  8. Releasates of riboflavin/UV‐treated platelets: Microvesicles suppress cytokine‐mediated endothelial cell migration/proliferation

    Article • Transfusion, February 2021, Wiley

    Professor Raymond Goodrich

  9. Preservation of neutralizing antibody function in COVID-19 convalescent plasma treated using a riboflavin and ultraviolet light-based pathogen reduction technology

    Article • February 2021, Cold Spring Harbor Laboratory Press

    Professor Raymond Goodrich

  10. Pilot Acute Safety Evaluation of Innocell™ Cancer Immunotherapy in Canine Subjects

    Article • Journal of Immunology Research, October 2020, Hindawi Publishing Corporation

    Professor Raymond Goodrich

  11. Pathogen reduction of SARS-CoV-2 virus in plasma and whole blood using riboflavin and UV light

    Article • PLOS One, May 2020, PLOS

    Professor Raymond Goodrich

  12. A novel cancer immunotherapy utilizing autologous tumour tissue

    Article • Vox Sanguinis, May 2020, Wiley

    Professor Raymond Goodrich

  13. Pathogen Reduction of SARS-CoV-2 Virus in Plasma and Whole Blood using Riboflavin and UV Light

    Article • May 2020, Cold Spring Harbor Laboratory Press

    Professor Raymond Goodrich

  14. Ignorance is not bliss

    Article • Transfusion, March 2018, Wiley

    Professor Raymond Goodrich

  15. Pathogen reduction of whole blood: utility and feasibility

    Article • Transfusion Medicine, September 2017, Wiley

    Professor Raymond Goodrich

  16. Efficiency of riboflavin and ultraviolet light treatment against high levels of biofilm-derivedStaphylococcus epidermidisin buffy coat platelet concentrates

    Article • Vox Sanguinis, April 2017, Wiley

    Professor Raymond Goodrich

  17. Red blood cells derived from whole blood treated with riboflavin and ultraviolet light maintain adequate survival in vivo after 21 days of storage

    Article • Transfusion, March 2017, Wiley

    Professor Raymond Goodrich

  18. Photochemical eradication of methicillin-resistantStaphylococcus aureusby blue light activation of riboflavin

    Article • Acta Ophthalmologica, February 2017, Wiley

    Professor Raymond Goodrich

  19. Reduced MHC alloimmunization and partial tolerance protection with pathogen reduction of whole blood

    Article • Transfusion, November 2016, Wiley

    Professor Raymond Goodrich

  20. Characterization of posttransfusionPlasmodium falciparuminfection in semi‐immune nonparasitemic patients

    Article • Transfusion, June 2016, Wiley

    Professor Raymond Goodrich

  21. Protein translation occurs in platelet concentrates despite riboflavin/UV light pathogen inactivation treatment

    Article • PROTEOMICS - CLINICAL APPLICATIONS, June 2016, Wiley

    Professor Raymond Goodrich

  22. Riboflavin and ultraviolet light: impact on dengue virus infectivity

    Article • Vox Sanguinis, June 2016, Wiley

    Professor Raymond Goodrich

  23. Effect of Plasmodium inactivation in whole blood on the incidence of blood transfusion-transmitted malaria in endemic regions: the African Investigation of the Mirasol System (AIMS) randomised controlled trial

    Article • The Lancet, April 2016, Elsevier

    DR MRS Shirley Owusu-Ofori, Professor Raymond Goodrich

  24. Reduced alloimmunization in mice following repeated transfusion with pathogen-reduced platelets

    Article • Transfusion, March 2016, Wiley

    Professor Raymond Goodrich

  25. Treatment of blood with a pathogen reduction technology using ultraviolet light and riboflavin inactivates Ebola virus in vitro

    Article • Transfusion, March 2016, Wiley

    Professor Raymond Goodrich

  26. Riboflavin-ultraviolet light pathogen reduction treatment does not impact the immunogenicity of murine red blood cells

    Article • Transfusion, December 2015, Wiley

    Professor Raymond Goodrich

  27. Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination

    Article • Journal of Visualized Experiments, August 2015, MyJove Corporation

    Professor Raymond Goodrich

  28. Treatment of Whole Blood With Riboflavin and UV Light

    Article • Shock, August 2015, Wolters Kluwer Health

    DR MRS Shirley Owusu-Ofori, Professor Raymond Goodrich

  29. Inactivation of viruses in platelet and plasma products using a riboflavin-and-UV-based photochemical treatment

    Article • Transfusion, March 2015, Wiley

    Professor Raymond Goodrich

  30. Large animal evaluation of riboflavin and ultraviolet light-treated whole blood transfusion in a diffuse, nonsurgical bleeding porcine model

    Article • Transfusion, January 2015, Wiley

    Professor Raymond Goodrich

  31. The effect of riboflavin and ultraviolet light on the infectivity of arboviruses

    Article • Transfusion, November 2014, Wiley

    Professor Raymond Goodrich

  32. Whole blood treated with riboflavin and ultraviolet light: quality assessment of all blood components produced by the buffy coat method

    Article • Transfusion, October 2014, Wiley

    Professor Raymond Goodrich

  33. Reduction ofLeishmania donovaniinfectivity in whole blood using riboflavin and ultraviolet light

    Article • Transfusion, August 2014, Wiley

    Professor Raymond Goodrich

  34. Chemical and Biological Mechanisms of Pathogen Reduction Technologies

    Article • Photochemistry and Photobiology, August 2014, Wiley

    Professor Raymond Goodrich

  35. Development of a mitochondrial DNA real-time polymerase chain reaction assay for quality control of pathogen reduction with riboflavin and ultraviolet light

    Article • Vox Sanguinis, June 2014, Wiley

    Professor Raymond Goodrich

  36. Plasma constituent integrity in pre-storage vs. post-storage riboflavin and UV-light treatment – A comparative study

    Article • Transfusion and Apheresis Science, December 2013, Elsevier

    Professor Raymond Goodrich

  37. Riboflavin and ultraviolet light treatment of platelets triggers p38MAPK signaling: inhibition significantly improves in vitro platelet quality after pathogen reduction treatment

    Article • Transfusion, March 2013, Wiley

    Professor Raymond Goodrich

  38. Immune modulation and lack of alloimmunization following transfusion with pathogen‐reduced platelets in mice

    Article • Transfusion, March 2013, Wiley

    Professor Raymond Goodrich

  39. Inactivation ofPlasmodiumspp. in plasma and platelet concentrates using riboflavin and ultraviolet light

    Article • Transfusion, January 2013, Wiley

    Professor Raymond Goodrich

  40. Development of a riboflavin and ultraviolet light-based device to treat whole blood

    Article • Transfusion, January 2013, Wiley

    Professor Raymond Goodrich

  41. Primary hemostatic capacity of whole blood: a comprehensive analysis of pathogen reduction and refrigeration effects over time

    Article • Transfusion, January 2013, Wiley

    Professor Raymond Goodrich

  42. A pilot study to assess the hemostatic function of pathogen-reduced platelets in patients with thrombocytopenia

    Article • Transfusion, December 2012, Wiley

    Professor Raymond Goodrich

  43. In Reply to: “Is the SCID mouse model applicable to human acute lung injury?”

    Article • Transfusion, November 2012, Wiley

    Professor Raymond Goodrich

  44. Fresh Whole Blood Use for Hemorrhagic Shock

    Article • Anesthesia & Analgesia, October 2012, Wolters Kluwer Health

    Professor Raymond Goodrich

  45. Riboflavin and ultraviolet light reduce the infectivity ofBabesia microtiin whole blood

    Article • Transfusion, July 2012, Wiley

    Professor Raymond Goodrich

  46. Photochemical inactivation of chikungunya virus in plasma and platelets using the Mirasol pathogen reduction technology system

    Article • Transfusion, May 2012, Wiley

    Professor Raymond Goodrich

  47. Treatment of whole blood with riboflavin plus ultraviolet light, an alternative to gamma irradiation in the prevention of transfusion-associated graft-versus-host disease?

    Article • Transfusion, May 2012, Wiley

    Professor Raymond Goodrich

  48. Preparation of cryoprecipitate from riboflavin and UV light-treated plasma

    Article • Transfusion and Apheresis Science, April 2012, Elsevier

    Professor Raymond Goodrich

  49. Quality of proteins in riboflavin and UV light-treated FFP during 1year of storage at −18°C

    Article • Transfusion and Apheresis Science, February 2012, Elsevier

    Professor Raymond Goodrich

  50. In response to Morrison-McKell and wehrli

    Article • Journal of Clinical Apheresis, January 2012, Wiley

    Professor Raymond Goodrich

  51. Improving blood safety and patient outcomes with pathogen reduction technology

    Article • Transfusion and Apheresis Science, December 2011, Elsevier

    Professor Raymond Goodrich

  52. In vitro quality of single-donor platelets treated with riboflavin and ultraviolet light and stored in platelet storage medium for up to 8 days

    Article • Transfusion, October 2011, Wiley

    Professor Raymond Goodrich

  53. Evaluating pathogen reduction of Trypanosoma cruzi with riboflavin and ultraviolet light for whole blood

    Article • Transfusion, August 2011, Wiley

    Professor Raymond Goodrich

  54. Establishment of the first International Repository for Transfusion-Relevant Bacteria Reference Strains: ISBT Working Party Transfusion-Transmitted Infectious Diseases (WP-TTID), Subgroup on Bacteria

    Article • Vox Sanguinis, July 2011, Wiley

    Professor Raymond Goodrich

  55. In reply

    Article • Transfusion, June 2011, Wiley

    Professor Raymond Goodrich

  56. The effect of pathogen reduction technology (Mirasol) on platelet quality when treated in additive solution with low plasma carryover

    Article • Vox Sanguinis, April 2011, Wiley

    Professor Raymond Goodrich

  57. FDA workshop on emerging infectious diseases: evaluating emerging infectious diseases (EIDs) for transfusion safety

    Article • Transfusion, March 2011, Wiley

    Professor Raymond Goodrich

  58. Protein stability of previously frozen plasma, riboflavin and UV light-treated, refrozen and stored for up to 2years at −30°C

    Article • Transfusion and Apheresis Science, February 2011, Elsevier

    Professor Raymond Goodrich

  59. In vivo viability of stored red blood cells derived from riboflavin plus ultraviolet light-treated whole blood

    Article • Transfusion, January 2011, Wiley

    Professor Raymond Goodrich

  60. Pathogen Reduction Technology Treatment of Platelets, Plasma and Whole Blood Using Riboflavin and UV Light

    Article • Transfusion Medicine and Hemotherapy, January 2011, Karger Publishers

    Professor Raymond Goodrich

  61. Generation of neutrophil priming activity by cell-containing blood components treated with pathogen reduction technology and stored in platelet additive solutions

    Article • Transfusion, December 2010, Wiley

    Professor Raymond Goodrich

  62. A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology

    Article • Transfusion, October 2010, Wiley

    Professor Raymond Goodrich, Professor Eric DECONINCK

  63. White blood cell inactivation after treatment with riboflavin and ultraviolet light

    Article • Transfusion, October 2010, Wiley

    Professor Raymond Goodrich

  64. Impact of pathogen reduction technology and storage in platelet additive solutions on platelet function

    Article • Transfusion, October 2010, Wiley

    Dr Miguel Lozano, Professor Raymond Goodrich

  65. Hemostatic function of buffy coat platelets in additive solution treated with pathogen reduction technology

    Article • Transfusion, August 2010, Wiley

    Professor Raymond Goodrich

  66. In vitro cell quality of buffy coat platelets in additive solution treated with pathogen reduction technology

    Article • Transfusion, May 2010, Wiley

    Professor Raymond Goodrich

  67. Defining “adequate” pathogen reduction performance for transfused blood components

    Article • Transfusion, March 2010, Wiley

    Professor Raymond Goodrich

  68. Errata

    Article • Transfusion, February 2010, Wiley

    Professor Raymond Goodrich

  69. Characterization of plasma protein activity in riboflavin and UV light-treated fresh frozen plasma during 2 years of storage at −30°C

    Article • Vox Sanguinis, February 2010, Wiley

    Professor Raymond Goodrich

  70. Design and development of a method for the reduction of infectious pathogen load and inactivation of white blood cells in whole blood products

    Article • Biologicals, January 2010, Elsevier

    Professor Raymond Goodrich

  71. Evaluation of the Mirasol platelet reduction technology system against Babesia microti in apheresis platelets and plasma

    Article • Transfusion, December 2009, Wiley

    Professor Raymond Goodrich

  72. Pathogen reduction technology (Mirasol®) treated single-donor platelets resuspended in a mixture of autologous plasma and PAS

    Article • Vox Sanguinis, October 2009, Wiley

    Professor Raymond Goodrich

  73. BLOOD COMPONENTS: Lack of antibody formation to platelet neoantigens after transfusion of riboflavin and ultraviolet light-treated platelet concentrates

    Article • Transfusion, August 2009, Wiley

    Professor Raymond Goodrich

  74. IMMUNOHEMATOLOGY: Understanding loss of donor white blood cell immunogenicity after pathogen reduction: mechanisms of action in ultraviolet illumination and riboflavin treatment

    Article • Transfusion, August 2009, Wiley

    Professor Raymond Goodrich

  75. A laboratory comparison of pathogen reduction technology treatment and culture of platelet products for addressing bacterial contamination concerns

    Article • Transfusion, June 2009, Wiley

    Professor Raymond Goodrich

  76. Evaluation of Different Preparation Procedures of Pathogen Reduction Technology(Mirasol®)-Treated Platelets Collected by Plateletpheresis

    Article • Transfusion Medicine and Hemotherapy, January 2009, Karger Publishers

    Professor Raymond Goodrich

  77. Evaluation of potential immune response and in vivo survival of riboflavin-ultraviolet light-treated red blood cells in baboons

    Article • Transfusion, January 2009, Wiley

    Professor Raymond Goodrich

  78. Reduction of prion infectivity in packed red blood cells

    Article • Biochemical and Biophysical Research Communications, December 2008, Elsevier

    Professor Raymond Goodrich

  79. Toxicity Testing of a Novel Riboflavin-Based Technology for Pathogen Reduction and White Blood Cell Inactivation

    Article • Transfusion Medicine Reviews, April 2008, Elsevier

    Professor Raymond Goodrich

  80. Treatment With Riboflavin and Ultraviolet Light Prevents Alloimmunization to Platelet Transfusions and Cardiac Transplants

    Article • Transplantation, November 2007, Wolters Kluwer Health

    Professor Raymond Goodrich

  81. Pathogen inactivation of Trypanosoma cruzi in plasma and platelet concentrates using riboflavin and ultraviolet light

    Article • Transfusion and Apheresis Science, October 2007, Elsevier

    Professor Raymond Goodrich

  82. Inactivation of Orientia tsutsugamushi in red blood cells, plasma, and platelets with riboflavin and light, as demonstrated in an animal model

    Article • Transfusion, February 2007, Wiley

    Professor Raymond Goodrich

  83. Mirasol PRT treatment of donor white blood cells prevents the development of xenogeneic graft-versus-host disease in Rag2?/??c?/?double knockout mice

    Article • Transfusion, September 2006, Wiley

    Professor Raymond Goodrich

  84. The Mirasol™ PRT system for pathogen reduction of platelets and plasma: An overview of current status and future trends

    Article • Transfusion and Apheresis Science, August 2006, Elsevier

    Professor Raymond Goodrich

  85. Correlation of in vitro platelet quality measurements with in vivo platelet viability in human subjects

    Article • Vox Sanguinis, May 2006, Wiley

    Professor Raymond Goodrich

  86. Functional inactivation of white blood cells by Mirasol treatment

    Article • Transfusion, April 2006, Wiley

    Professor Raymond Goodrich

  87. Pathogen inactivation of Leishmania donovani infantum in plasma and platelet concentrates using riboflavin and ultraviolet light

    Article • Vox Sanguinis, February 2006, Wiley

    Professor Raymond Goodrich

  88. Platelet glycolytic flux increases stimulated by ultraviolet-induced stress is not the direct cause of platelet morphology and activation changes: possible implications for the role of glucose in platelet storage

    Article • Transfusion, November 2005, Wiley

    Professor Raymond Goodrich

  89. Comparison of computerized formulae for determination of platelet recovery and survival

    Article • Transfusion, July 2005, Wiley

    Professor Raymond Goodrich

  90. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction

    Article • Transfusion, June 2005, Wiley

    Professor Raymond Goodrich

  91. Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates

    Article • Transfusion, June 2005, Wiley

    Professor Raymond Goodrich

  92. Evaluation of platelet mitochondria integrity after treatment with Mirasol pathogen reduction technology

    Article • Transfusion, June 2005, Wiley

    Professor Raymond Goodrich

  93. An Action Spectrum of the Riboflavin-photosensitized Inactivation of Lambda Phage¶

    Article • Photochemistry and Photobiology, January 2005, Wiley

    Professor Raymond Goodrich

  94. Pathogen reduction of buffy coat platelet concentrates using riboflavin and light: comparisons with pathogen-reduction technology-treated apheresis platelet products

    Article • Vox Sanguinis, August 2004, Wiley

    Professor Raymond Goodrich

  95. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light

    Article • Transfusion, May 2004, Wiley

    Professor Raymond Goodrich

  96. Riboflavin and UV-Light Based Pathogen Reduction: Extent and Consequence of DNA Damage at the Molecular Level

    Article • Photochemistry and Photobiology, January 2004, Wiley

    Professor Raymond Goodrich

  97. Separation, Identification and Quantification of Riboflavin and its Photoproducts in Blood Products using High-performance Liquid Chromatography with Fluorescence Detection: A Method to Support Pathogen Reduction Technology¶

    Article • Photochemistry and Photobiology, January 2004, Wiley

    Professor Raymond Goodrich

  98. The design and development of selective, photoactivated drugs for sterilization of blood products

    Article • Drugs of the Future, January 1997, Thomson Reuters (Scientific) Inc. & Affiliates

    Professor Raymond Goodrich

  99. Photochemical and Photophysical Studies of 3‐Amino‐6‐lodoacridine and the Inactivation of λ Phage

    Article • Photochemistry and Photobiology, October 1996, Wiley

    Professor Raymond Goodrich

  100. Measurement of Transmitted Light as an Indicator of Cryopreserved Platelet Viability

    Article • Pathophysiology of Haemostasis and Thrombosis, January 1996, Karger Publishers

    Professor Raymond Goodrich

  101. Survival of lyophilized and reconstituted human red blood cells in vivo

    Article • Transfusion Clinique et Biologique, January 1995, Elsevier

    Professor Raymond Goodrich

  102. Selective inactivation of viruses in the presence of human platelets: UV sensitization with psoralen derivatives.

    Article • Proceedings of the National Academy of Sciences, June 1994, Proceedings of the National Academy of Sciences

    Professor Raymond Goodrich

  103. DRAMATIC IMPROVEMENTS IN VIRAL INACTIVATION WITH BROMINATED PSORALENS, NAPHTHALENES AND ANTHRACENES

    Article • Photochemistry and Photobiology, July 1993, Wiley

    Professor Raymond Goodrich

  104. Refrigerated storage of lyophilized and rehydrated, lyophilized human red cells

    Article • Transfusion, April 1993, Wiley

    Professor Raymond Goodrich

  105. Preservation of metabolic activity in lyophilized human erythrocytes.

    Article • Proceedings of the National Academy of Sciences, February 1992, Proceedings of the National Academy of Sciences

    Professor Raymond Goodrich

  106. EPR spectroscopy of triplet aryl nitrenes covalently bound to .alpha.-chymotrypsin. Application of low-temperature methods to photoaffinity labeling

    Article • Journal of the American Chemical Society, September 1988, American Chemical Society (ACS)

    Professor Raymond Goodrich

  107. Spectroscopy Of Nitrenes Bound To ∝-Chymotrypsin

    Article • February 1988, SPIE

    Professor Raymond Goodrich